Core Insights - Dongyao Pharmaceutical reported a revenue of 622 million yuan for the nine months ending September 30, 2025, representing a 23% decrease compared to the same period last year, primarily due to intensified market competition for self-developed products [1] - The company experienced a net loss of 3.37 million yuan during this period, contrasting with a net profit of 35.4 million yuan in the same period last year [1] - As of September 30, 2025, the company's current assets totaled 656 million yuan, non-current assets were 721 million yuan, current liabilities amounted to 266 million yuan, non-current liabilities were 385 million yuan, and total net assets slightly decreased to 726 million yuan from 730 million yuan as of December 31, 2024 [1] Financial Performance - Revenue for the nine-month period was 622 million yuan, down 23% year-on-year [1] - Net loss recorded was 3.37 million yuan, compared to a net profit of 35.4 million yuan in the previous year [1] - Total net assets decreased slightly to 726 million yuan from 730 million yuan [1] Balance Sheet Overview - Current assets stood at 656 million yuan [1] - Non-current assets were reported at 721 million yuan [1] - Current liabilities were 266 million yuan, while non-current liabilities were 385 million yuan [1]
东曜药业：前三季度营收为6.22亿元，自研产品市场竞争愈加激烈